Thus, the proportion of tumor samples positive with EGFR and MUC1 was estimated to be 97.5% (Figure 5G), which indicated that a large population of LUAD patients could potentially benefit from EGFR-MUC1 dual-targeting therapies. The gene discussed is MUC1; the disease is neoplasm.